

# Pre-clinical development of anginex and design of small-peptide mimetics

Citation for published version (APA):

Dings, R. P. M. (2003). *Pre-clinical development of anginex and design of small-peptide mimetics*. [Doctoral Thesis, Maastricht University]. Universiteit Maastricht. <https://doi.org/10.26481/dis.20030703rd>

## Document status and date:

Published: 01/01/2003

## DOI:

[10.26481/dis.20030703rd](https://doi.org/10.26481/dis.20030703rd)

## Document Version:

Publisher's PDF, also known as Version of record

## Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

## General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

[www.umlib.nl/taverne-license](http://www.umlib.nl/taverne-license)

## Take down policy

If you believe that this document breaches copyright please contact us at:

[repository@maastrichtuniversity.nl](mailto:repository@maastrichtuniversity.nl)

providing details and we will investigate your claim.

# Statements

as part of the thesis

Pre-clinical development of anginex  
and design of small-peptide mimetics

by Ruud P.M. Dings  
Maastricht, 3 July 2003

1. Anti-parallel  $\beta$ -sheet structure and preponderance of positively charged and hydrophobic residues, is the recurring structural/compositional theme for most anti-angiogenic compounds.  
(this thesis)
2. Partial peptide-mimetic 6DBF7 is the first EC-specific molecule designed as a substitute for an angiostatic inhibitory peptide.  
(this thesis)
3. Genentech's Avastin, like anginex, proves that angiogenesis inhibition can be a very powerful therapeutic treatment against cancer in combination with conventional chemotherapy.  
(this thesis)
4. There is no such thing as a panacea.
5. Having hope can be naïve, but sometimes that's all one has.
6. Deadlines increase productivity, but unfortunately not often quality.
7. The nearly one to one exchange value between the American Dollar and the Euro in 2002 made it very clear that the stipend of the average Dutch Ph.D. student is much higher than that of the average American Ph.D. student.
8. Blessed be the people with a conscience, for they are the cursed of the world.
9. A result of being perfectly satisfied is that you always desire more.